FeesSafety
Pluang+

Wegovy trial shows significant BMI reduction in obese children aged 6-12, with no safety concerns.

Market News
16 Nov 2026, 17:00 WIB
CNBC
View Source
Bullish
Wegovy trial shows significant BMI reduction in obese children aged 6-12, with no safety concerns.

Novo's late-stage trial results reveal Wegovy significantly lowers BMI in children aged 6 to under 12 with obesity, reducing BMI by up to 19.7 percentage points compared to placebo over 68 weeks. The drug, already approved for those 12 and older, shows promise as the first medication option for younger children, with no observed safety issues related to growth or puberty. This development addresses a critical gap in childhood obesity treatment, a condition affecting millions globally and linked to serious health risks. Further research is needed to understand long-term effects and treatment maintenance into adulthood.

As of Nov 16, 2026 22:12 WIB, Novo Nordisk A/S (NVO) shares are trading at USD 41.99 on Pluang, showing a modest gain of 0.88% for the day. The company holds a significant market cap of $181.43 billion and offers a dividend yield of 4.32%. This steady performance accompanies Novo's announcement of promising trial results for Wegovy in reducing BMI among children with obesity.

More News (NVO)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App